Compare Heron Therapeutics Inc (HRTX) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.94. The key difference: JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | JEPQ | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $61.46 |
52-Week Low | $0.32 | $53.77 |
Enterprise Value | $168.21M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
JEPQ trades at $60.01, up 0.55% today, with a bullish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with an options income strategy, generating monthly distributions. Recent news highlights its role in retirement income portfolios but notes tax implications for distributions. Key support sits at $59, with resistance at $60.
The outlook remains positive for income-seeking investors, supported by institutional buying and media coverage. Risks include tax treatment of distributions and market volatility affecting the underlying Nasdaq holdings. Analyst sentiment is mixed due to high RSI levels suggesting potential overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
